India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, ...

AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.

Organon Canada and Henlius expand access to denosumab treatments with launch of BILDYOS® and TUZEMTY® biosimilars to PROLIA and XGEVA ...

Much of the current drug-pricing agenda proposed by President Biden and by Congress is based on the belief that greater government control — rather than free market competition — is the best way to ...

Get all latest & breaking news on Biosimilars Market. Watch videos, top stories and articles on Biosimilars Market at moneycontrol.com.

Driving revenue growth and earnings growth are two different things.

With seven biosimilars currently on the market and 18 biosimilars approved by the FDA as of April 2019, one question is sparking a lot of debate: What should the scientific, or nonproprietary, names ...

A new report from AHIP indicates that biosimilars have the potential to garner savings of $180 billion over 5 years, but there needs to be a review of the approval process for interchangeability to ...

Key Points Interested in Alvotech? Here are five stocks we like better. Alvotech says it is at an "inflection point," with management expecting five U.S. biosimilars on the market by year-end after ...

Created via the Biologics Price Competition and Innovation Act, the biosimilar class of drugs was conceived as an opportunity to introduce competition for commonly used biologics following loss of ...

The FDA has proposed a radical change to the regulatory requirements for bringing biosimilars to market, in a bid to accelerate the rollout of cheaper versions of off ...

Samsung Bioepis and Organon have expanded their development and commercialization agreement, whereby Organon will obtain commercialization rights in Canada to Pyzchiva, Samsung Bioepis’s Stelara.